Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets
NCT05317858
This study is recruiting at 9 US sites in 6 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier opening with Exablate Model 4000 Type 2.0/2.1 for the treatment of NSCLC brain metastases in patients who are undergoing planned FDA approved, on-label systemic therapy utilizing immune checkpoint inhibitors.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Brain Tumor
- Non Small Cell Lung Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 18 to 100 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- InSightec
- Last updated on ClinicalTrials.gov
- October 13, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- Hoag Memorial Hospital Presbyterian · Newport Beach, CA
Florida · 3
- Broward Health · Fort Lauderdale, FL
- Miami Cancer Institute at Baptist Health · Miami, FL
- Moffitt Cancer Center · Tampa, FL
Maryland · 1
- University of Maryland · Baltimore, MD
North Carolina · 2
- Duke University · Durham, NC
- Atrium Health Wake Forest Baptist · Winston-Salem, NC
Oregon · 1
- Oregon Health & Science University · Portland, OR
Rhode Island · 1
- Rhode Island Hospital · Providence, RI
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.